MRX 4

Drug Profile

MRX 4

Alternative Names: MRX-4

Latest Information Update: 28 May 2015

Price : $50

At a glance

  • Originator Morria Biopharmaceuticals
  • Developer Celsus Therapeutics
  • Class Anti-inflammatories
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Allergic rhinitis

Most Recent Events

  • 06 Mar 2013 Morria Biopharmaceuticals is now called Celsus Therapeutics
  • 31 Dec 2012 Celsus Therapeutics plans a phase IIb trial for Allergic rhinitis in Austria
  • 17 Jun 2010 Final safety and efficacy data from a phase II trial in Allergic rhinitis released by Morria Biopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top